What Is Homoharringtonine?
Homoharringtonine (HHT) is a natural alkaloid derived from plants of the *Cephalotaxus* genus. Its uniqueness in the spectrum of antitumor drugs primarily stems from its mechanism of action, which does not rely on classic kinase inhibition or DNA damage mechanisms. Unlike most chemotherapeutic drugs or molecular targeted therapies, HHT directly acts on the A-site of eukaryotic ribosomes, inhibiting the protein translation elongation phase by blocking the binding of aminoacyl-tRNA to the mRNA-ribosome complex. This mechanism results in highly selective cytotoxicity in malignant cells that are highly dependent on continuous protein synthesis for survival.
Fig.1 Molecular structure of HHT highlighting the cephalotaxine core[1].
From a chemical biology perspective, HHT does not simply "inhibit protein synthesis," but rather induces irreversible apoptotic signals in tumor cells by rapidly reducing the intracellular levels of short-lived oncogenic proteins (such as MCL-1 and c-Myc). This characteristic explains the molecular basis for its continued efficacy against various drug-resistant leukemia cells and establishes its independent pharmacological status as a "non-kinase inhibitor anti-leukemia drug."
Order high-purity Homoharringtonine (CAS 26833-87-4) from Alfa Chemistry to advance protein synthesis inhibition and drug-resistance research. View and purchase now!
| Catalog | Product Name | Price |
| ACM26833874-3 | Homoharringtonine | Inquiry |
How Does Homoharringtonine Regulate Cell Cycle and Apoptosis?
At the cellular level, the inhibition of tumor cell proliferation by HHT is not a single event, but rather a multi-layered regulatory process. Studies show that HHT can simultaneously block cancer cells from entering the S phase from the G1 phase, and from transitioning from the G2 phase to the M phase, causing significant cell cycle arrest. This "dual-node blockade" effect is closely related to its inhibition of the translation of key cell cycle regulatory proteins.
Further molecular studies show that HHT can significantly downregulate anti-apoptotic proteins (such as Bcl-2 and MCL-1) and activate the Caspase-dependent apoptotic pathway, thereby triggering programmed cell death without relying on DNA damage. This characteristic is of great clinical significance: it reduces the long-term safety risks associated with genotoxicity and provides greater strategic flexibility for combination therapy.
Fig.2 Schematic diagram illustrating the effects of HHT on cytotoxic, anti-proliferative, cell cycle arrest, and anti-metastatic signaling pathways in hematological tumor cells[2].
What Types of Malignancies Can Homoharringtonine Target?
The clinical and research applications of HHT have significantly expanded beyond its initial focus on hematological malignancies. While its most representative indications remain chronic myeloid leukemia (CML), acute myeloid leukemia (AML), and myelodysplastic syndromes (MDS), recent research has increasingly revealed its inhibitory potential in various solid tumor models.
In breast cancer, hepatocellular carcinoma, and colorectal cancer models, HHT has been shown to inhibit tumor cell proliferation and reduce migration and invasion by regulating key oncogenic signaling pathways such as PI3K/AKT and Wnt/β-catenin. This dual mode of action—translational inhibition combined with signaling pathway remodeling—makes HHT an important tool molecule for studying tumors characterized by protein homeostasis imbalance.
Fig.3 The molecular mechanisms of HHT in malignant tumors[2].
How Has Homoharringtonine Been Approved and Used Clinically?
Omacetaxine mepesuccinate (a semi-synthetic, water-soluble form of HHT) was approved by the US FDA in October 2012 for the treatment of chronic or accelerated-phase CML patients who have failed at least two tyrosine kinase inhibitors (TKIs). This approval marked HHT as the second FDA-approved non-kinase inhibitor for CML.
In China and some other countries, HHT has a wider range of clinical applications, covering multiple stages of CML, AML, and MDS. Its administration is primarily subcutaneous injection. Compared to earlier rapid intravenous administration regimens, this method significantly reduces the risk of cardiovascular adverse reactions while improving treatment controllability and patient tolerability.
Fig.4 The major mechanism of action of omacetaxine mepesuccinate[3].
How Is Homoharringtonine Being Optimized for Future Therapeutic Use?
A key current research direction is the structural modification and derivative development of homoharringtonine. New generation candidate molecules (such as BS-HH-002) aim to enhance antitumor selectivity and reduce systemic toxicity while maintaining their translational repressive activity.
At the molecular mechanism level, recent studies suggest that HHT may exhibit more precise therapeutic potential in specific molecular subtypes of leukemia by interfering with the TET1/5-hmC epigenetic regulatory axis or directly inhibiting the expression of key oncogenic proteins such as FLT3. These findings are driving the transformation of HHT from a "classic natural product anticancer drug" to a chemical biology tool molecule with a well-defined mechanism and stratified application.
Fig.5 Improved PK/PD of BS-HH-002 compared with HHT[4].
Frequently Asked Questions About Homoharringtonine
- What makes homoharringtonine different from tyrosine kinase inhibitors?
It doesn't act on kinase active sites but rather weakens tumor cells' dependence on oncogenes by inhibiting protein translation.
- How fast does homoharringtonine exert its antitumor effect?
Because it directly affects protein synthesis, HHT often significantly reduces the levels of short-lived oncogenes in a relatively short time.
- Can homoharringtonine be combined with other anticancer agents?
Its non-DNA damage and non-kinase inhibition mechanism makes it highly compatible with combination therapies.
- Is homoharringtonine suitable for drug resistance studies?
Yes, especially in TKI-resistant CML models, HHT is widely used in mechanistic and reversal strategy studies.
- Why is homoharringtonine still actively studied despite being an old drug?
Because its mechanism of action is highly unique, and new molecular targets and applications are constantly being discovered.
Customers considering using homoharringtonine may also be interested in the following products:
References
- Khatua S, et al. Homoharringtonine: updated insights into its efficacy in hematological malignancies, diverse cancers and other biomedical applications. European Journal of Medical Research. (2009).
- Wang W, et al. Homoharringtonine: mechanisms, clinical applications and research progress. Front Oncol. (2025).
- Chen Y, et al. Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia. OncoTargets and Therapy. (2014).
- Wang A, et al. Therapeutic effects of an innovative BS-HH-002 drug on pancreatic cancer cells via induction of complete MCL-1 degradation. Translational Oncology. (2022).
Please kindly note that our products are for research use only.
